Health Innovation

We are de-risking biomedical innovations, turning biomedical knowledge into social and economic value.

Health Innovation Assessment

Mercury Pharmaceuticals

Innovators and start-ups in healthcare and biotech are experts in their innovation’s scientific and technical domain but often struggle with navigating the complex world of the healthcare industry.

If you want to objectively show the advantages and competitiveness of your innovation to potential investors, future users, (reimbursement) payers or even the media, you can greatly benefit from Mercury Pharmaceuticals’s Health Innovation Assessment solution.

By making use of robust methods to collect and analyse data, Health Innovation Assessment (HIA) aims to comprehensively assess the added value of (bio-)medical and healthcare innovations. HIA takes into account true multi-stakeholder perspectives on value assessment and the realm of marketplace decision making.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

STAY INFORMED!

Sleep apnea and erectile dysfunction share a stronger link than expected

8

Jul 2026

Sleep apnea and erectile dysfunction share a stronger link than expected

A systematic review and meta-analysis of 8 observational studies found that greater obstructive sleep apnea severity was associated with poorer erectile function, with higher AHI linked to lower IIEF scores and higher minimum oxygen saturation linked to higher IIEF scores. The authors caution that the evidence remains observational, heterogeneous, and low certainty, so the findings support targeted screening rather than proving causality.

READ MORE

Why Us?

KNOWLEDGE OF RESEARCH ENVIRONMENT

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.

UNDERSTANDING INDUSTRIAL NEEDS

Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.

FOCUSED PROJECT MANAGEMENT

Smart approach to project management that helps speed up development stages and decision making.

INVESTMENT CAPABILITY

Availability of own investment up to 2m€ per project allows us to reach the next value milestone.